Leandro Bueno Bergantin

Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil): biomedicine (2008), MSc (2010) and PhD (2014); with a research visiting period in UAM (Spain). His research involves cell signalling mediated by Ca2+ and cAMP, including its role in neuropsychopharmacology, autonomic and cardiovascular pharmacology, and cancer. Dr. Bergantin´s research work solved the enigma of the paradoxical effects produced by L-type Ca2+ channel blockers (CCB), which was published in Cell Calcium (JCR: 4.87) and achieved the position ´ScienceDirect TOP 25 Hottest Articles´ (ranked #1 on the TOP 25 for Cell Calcium, 2013). This discovery generated 17 articles published in international journals indexed in PubMed, in which 14 of them Dr. Bergantin is the sole author; e.g. Cancer Letters (JCR: 7.36), Pharmacological Research (JCR: 5.89), Current Protein & Peptide Science (JCR: 2.52), Current Pharmaceutical Design (JCR: 2.20), Psychiatry Research (JCR: 2.11), Anti-Cancer Agents in Medicinal Chemistry (JCR: 2.04). Briefly, since 1975 several clinical and experimental studies have reported that acute and chronic administration of L-type CCB, such as nifedipine, produces reduction in arterial pressure associated with a paradoxical increase of sympathetic activity. In 2013, Dr. Bergantin discovered that this paradoxical increase in sympathetic activity produced by L-type CCB is due to the interaction of Ca2+/cAMP signalling, then opening new avenues for biomedical research, e.g. neurological and psychiatry diseases, cancer, diabetes, and asthma. Dr. Bergantin is member of several editorial boards of international journals, and has been frequently invited to be honorable guest in international conferences as well as to participating in media interviews. His last book is entitled ´The “Calcium Paradox” and its Impact on Neurological and Psychiatric Diseases´ (publisher: Cambridge Scholars Publishing. NLM ID: 101734546).
Selected references (source: PubMed)
1. Bergantin L. The complex link between schizophrenia and dementia: Targeting Ca2+/cAMP signalling. Curr Pharm Des. 2020 Mar 18. doi: 10.2174/1381612826666200318144521. Epub ahead of print. PMID: 32186273.
2. Bergantin LB. A Hypothesis for the Relationship between Depression and Cancer: Role of Ca2+/cAMP Signalling. Anticancer Agents Med Chem. 2020 Feb 19. doi: 10.2174/1871520620666200220113817. Epub ahead of print. PMID: 32077833.
3. Bergantin LB. The interactions between Alzheimer´s disease and major depression: Role of Ca2+ channel blockers and Ca2+/cAMP signalling. Curr Drug Res Rev. 2020 Feb 16. doi: 10.2174/2589977512666200217093356. Epub ahead of print. PMID: 32065096.
4. Bergantin LB. The interplay between depression and Parkinson´s disease: learning the link through Ca2+/cAMP signalling. Curr Protein Pept Sci. 2020 Feb 6. doi: 10.2174/1389203721666200206161912. Epub ahead of print. PMID: 32026774.
5. Bergantin LB. A link between brain insulin resistance and cognitive dysfunctions: targeting Ca2+/cAMP signalling. Cent Nerv Syst Agents Med Chem. 2020 Jan 29. doi: 10.2174/1871524920666200129121232. Epub ahead of print. PMID: 31995022.
6. Bergantin LB. The Interplay Between Asthma and Other Diseases: Role of Ca2+/cAMP Signalling. Endocr Metab Immune Disord Drug Targets. 2020;20(3):321-327. doi: 10.2174/1871530319666190828145854. PMID: 31456527.
7. Bergantin LB. Diabetes and Parkinson's Disease: Debating the Link Through Ca2+/cAMP Signalling. Curr Diabetes Rev. 2020;16(3):238-241. doi: 10.2174/1573399815666190711113644. PMID: 31291877.
8. Bergantin LB. Depression Rises the Risk of Hypertension Incidence: Discussing the Link through the Ca2+/cAMP Signalling. Curr Hypertens Rev. 2020;16(1):73-78. doi: 10.2174/1573402115666190116095223. PMID: 30648516.
9. Bergantin LB. Diabetes and cancer: Debating the link through Ca2+/cAMP signalling. Cancer Lett. 2019 Apr 28;448:128-131. doi: 10.1016/j.canlet.2019.02.017. Epub 2019 Feb 13. PMID: 30771427.
10. Bergantin LB. Debating the "bidirectional link" between diabetes and depression through the Ca2+/cAMP signalling: Off-label effects of Ca2+ channel blockers. Pharmacol Res. 2019 Mar;141:298-302. doi: 10.1016/j.phrs.2019.01.008. Epub 2019 Jan 9. PMID: 30639385.
11. Bergantin LB. Hypertension, Diabetes and Neurodegenerative Diseases: Is there a Clinical Link through the Ca2+/cAMP Signalling Interaction? Curr Hypertens Rev. 2019;15(1):32-39. doi: 10.2174/1573402114666180817113242. PMID: 30117399.
12. Bergantin LB. The clinical link between depression and obesity: Role of Ca2+/cAMP signalling. Psychiatry Res. 2020 Sep;291:113167. doi: 10.1016/j.psychres.2020.113167. Epub 2020 Jun 1. PMID: 32562933.
13. Bergantin LB. A link among schizophrenia, diabetes, and asthma: Role of Ca2+/cAMP signaling. Brain Circ. 2020 Sep 30;6(3):145-151. doi: 10.4103/bc.bc_66_19. PMID: 33210037; PMCID: PMC7646390.
14. Bergantin LB. Common issues among asthma, epilepsy, and schizophrenia: from inflammation to Ca2+/cAMP signalling. Antiinflamm Antiallergy Agents Med Chem. 2020 Nov 10. doi: 10.2174/1871523019999201110192029. Epub ahead of print. PMID: 33176668.

Main Menu

See Also

Main Menu